Table 4 Intergroup comparison of change with treatment in evaluation results
From: Splinting in carpal tunnel syndrome—should we use it during the daytime?
Group 1 n (wrists) = 20 Median (IQR 25–75%), n (%)* | Group 2 n (wrists) = 28 Median (IQR 25–75%), n (%)* | Group 3 n (wrists) = 22 Median (IQR 25–75%), n (%)* | P value | ||||
|---|---|---|---|---|---|---|---|
**p | Groups 1–2a | Groups 1–3a | Groups 2–3a | ||||
VAS | 0.0 (0.0–17.50) | − 10.0 (− 30.0 to 0.0) | − 20.0 (− 30.0 to − 10.0) | 0.005 | 0.018 | 0.001 | 0.015 |
Median DSAP | 0.75 (− 2.02 to 1.35) | 1.40 (− 17.95 to 1.55) | 0.65 (− 3.57 to 6.30) | 0.083 | |||
Median SCV | 0.0 (− 1.35 to 1.55) | 1.20 (− 2.87 to 2.12) | 0.60 (− 2.22 to 0.0) | 0.132 | |||
Median CMAP | 0.0 (− 1.07 to 0.45) | 0.10 (− 2.55 to 0.27) | 0.05 (− 1.05 to 0.32) | 0.216 | |||
Median DML | 0.0 (− 0.01 to 0.04) | − 0.01 (− 0.15 to 0.39) | − 0.20 (− 0.73 to 1.24) | 0.967 | |||
Median MCV | 0.0 (− 1.0 to 0.0) | 0.0 (− 7.0 to 0.0) | 0.0 (0.0–0.67) | 0.138 | |||
BCTQ-SSS | 0.0 (0.0–0.20) | 0.0 (− 0.09 to 0.61) | − 0.36 (− 1.18 to − 0.18) | 0.974 | |||
BCTQ-FSS | 0.0 (− 0.25 to 0.0) | − 0.12 (− 0.09 to 0.84) | − 1.25 (− 1.71 to − 0.32) | 0.039 | 0.808 | 0.004 | 0.020 |
NHP-pain | 0.0 (− 1.90 to 0.0) | 0.0 (0.0–0.0) | − 16.88 (− 28.44 to 0.0) | 0.005 | 0.535 | 0.001 | 0.003 |
NHP-ER | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–18.74) | 0.273 | |||
NHP-sleep | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–26.59) | 0.525 | |||
NHP-energy | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.756 | |||
NHP-PA | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (− 5.49 to − 0.0) | 0.059 | |||
NHP-SI | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | − 9.0 (− 20.13 to 0.0) | 0.003 | 0.462 | 0.001 | 0.001 |
NHP-total | 0.0 (0.0–0.0) | − 9.87 (0.0–54.18) | − 26.2 (− 81.42 to 0.0) | 0.015 | 0.058 | 0.001 | 0.012 |